In this edition of our Guidelines International Series, we delve into the British Society for Rheumatology (BSR), the foremost specialist medical society in the UK for rheumatology and musculoskeletal professionals dedicated to enhancing the quality of life for children and adults with rheumatic and musculoskeletal diseases. The BSR is well known for its comprehensive collection […]
Read MoreIn this edition of the Guidelines+ Monographs Series will delve into the medication alirocumab, marketed under the brand name Praluent® from Regeneron. Praluent (alirocumab) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, as […]
Read More
On October 25, 2022, the US Food and Drug Administration (FDA) granted approval for Johnson & Johnson’s Tecvayli® (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma. This approval is specifically for patients who have previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug, and […]
Read MoreOur latest edition of the Guidelines+ Monographs Series will delve into the medication irinotecan liposome injection, marketed under the brand name Onivyde® by Ipsen. Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan used in the treatment of pancreatic adenocarcinoma. Onivyde is indicated in combination with oxaliplatin, fluorouracil and leucovorin, […]
Read More
AstraZeneca and Daiichi Sankyo have collaboratively submitted a new Biologics License Application (BLA) for accelerated approval in the United States for datopotamab deruxtecan (Dato-DXd). This application aims to provide treatment for adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) who have previously undergone systemic therapies, including […]
Read More
The 66th ASH Annual Meeting and Exposition took place from December 7-10, 2024, in San Diego, California, as well as online. This event is the premier hematology gathering of the year, attracting over 30,000 health professionals, clinicians, researchers, educators, and other industry experts. Attendees can expect a multitude of sessions, thousands of abstracts, and numerous […]
Read More
The American College of Cardiology (ACC) has recently released guidance for diagnosing and treating acute myocarditis in adult patients. The 2024 ACC Expert Consensus Decision Pathway (ECDP) on Strategies and Criteria for the Diagnosis and Management of Myocarditis outlines a 5-step care pathway, along with recommendations for resuming strenuous physical activity. Additionally, the guidelines aim […]
Read More
Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease, primary RLS, and idiopathic RLS, is a neurological disorder characterized by unpleasant sensations in the legs and an irresistible urge to move them. The Centers for Disease Control (CDC) estimates that up to 7-10% of the US population may be affected by RLS, with onset possible […]
Read More
Welcome to the latest edition of our Guideline Spotlight, where we will explore the valuable insights and key takeaways from the most recent guideline releases. Today, our focus is on the American Diabetes Association’s (ADA) latest edition of their Standards of Care in Diabetes, which was released on December 9, 2024. This edition consolidates all […]
Read MoreThe American Urological Association (AUA) is currently seeking feedback and comments on their draft vasectomy guideline. AUA members and other interested parties will have the opportunity to review the draft guideline starting in January 2025, for a period of approximately two weeks. Prior to receiving a copy of the draft guideline, all reviewers must disclose […]
Read More